Centanafadine Hydrochloride for Attention Deficit Hyperactivity Disorder (ADHD)
This trial is to see if a new medicine for ADHD is safe and tolerated by kids.
- Attention Deficit Hyperactivity Disorder (ADHD)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Could you please inform me of the risks associated with taking Centanafadine Hydrochloride?
"Centanafadine Hydrochloride, which is currently in Phase 3 clinical trials, was given a safety rating of 3. This reflects the presence of some efficacy data as well as multiple rounds of supportive safety data."
Are geriatric patients accepted into this program?
"According to the information provided, patients that meet the age criteria of 4-17 years old are eligible for this trial. There are a total of 112 studies targeting people under 18 and 40 for those over 65."
To whom is this study available?
"Patients that have been diagnosed with attention deficit hyperactivity disorder and are between the ages of 4-17 may be accepted into this clinical trial. Currently, the study is looking to enroll around 700 patients."
Are people with the target condition eligible to participate in this research right now?
"Yes, this is an ongoing trial that was posted on February 24th, 2022 and last updated August 31st, 2022. The study will take place at a single site but 700 patients are needed for the clinical trial."